Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India
Roy, P Islam, R Saha, D Gogoi, M Kumar, MD Arora, N Parihar, M Krishnan, Shekhar Saha, Vaskar
Roy, P
Islam, R
Saha, D
Gogoi, M
Kumar, MD
Arora, N
Parihar, M
Krishnan, Shekhar
Saha, Vaskar
Citations
Altmetric:
Abstract
The feasibility of bortezomib (BZB) in induction and reduced cytarabine doses in intensification was evaluated in children with relapsed acute lymphoblastic leukaemia (rALL) at a single centre in India. Of 55 children with rALL, 23 received supportive care and 7 refused treatment, with a median survival of 2 (interquartile range 1-6) months. Twenty-two (88%) of 25 children who were treated achieved second remission and 9 (69%) of 13 had end-of-induction minimal residual disease of <10-4 . The lower cytarabine dose was associated with decreased hospitalisation. One-year event-free and overall survival for the treated group was 74á7% (95% confidence interval 52-88) and 79á6% (58-91) respectively.
Description
Date
2019
Publisher
Collections
Keywords
Type
Article
Citation
Roy P, Islam R, Saha D, Gogoi M, Kumar Mishra D, Arora N, et al. Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India. Br J Haematol. 2019 Jun 5.